Treatment optimisation in multiple sclerosis

Neurological Sciences

Volumn 26, Issue SUPPL. 4, 2005, Pages

  Zaffaroni, M ^a  

^a Azienda Ospedaliera S Antonio Abate di Gallarate   (Italy)

Author keywords

Clinicalg uidelines; Disease modifying agents; Multiple sclerosis; Treatment optimisation

Indexed keywords

BETA INTERFERON; GLATIRAMER; NEUTRALIZING ANTIBODY;

ARTICLE; CONSENSUS; DISEASE COURSE; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL DISABILITY; POSTMARKETING SURVEILLANCE; RELAPSE; SYMPTOMATOLOGY; TREATMENT FAILURE; VALIDATION PROCESS;

ADJUVANTS, IMMUNOLOGIC; DECISION SUPPORT TECHNIQUES; DISABILITY EVALUATION; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 30644467628     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-005-0513-7     Document Type: Article

References (35)

1. Tremlett HL, Oger J (2003) Interrupted therapy. Stopping and switching of the beta-interferons prescribed for MS. Neurology 61:551-554
2. Dubois BD, Keenan E, Porter BE et al (2003) Interferon β in multiple sclerosis: Experience in a British specialist multiple sclerosis centre. J Neurol Neurosurg Psychiatry 74:946-949
3. Milanese C, La Mantia L, Palumbo R et al (2003) A postmarketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: Different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 74:1689-1692
4. Waubant E, Vukusic S, Gignoux L et al (2003) Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 61:184-189
5. Goodin DS, Frohman EM, Garmany GP et al (2002) Disease modifying therapies in multiple sclerosis. Neurology 58:169-178
6. Trojano M (2005) Interferon b treatment in relapsing-remitting multiple sclerosis: A post-marketing study. Ital J Neurol Sci (in press)
7. Weinshenker BG, Bass B, Rice GP et al (1989) The natural history of multiple sclerosis: A geographically based study. Clinical course and disability. Brain 112:1419-1428
8. Lublin FD, Baier M, Cutter G (2003) Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61:1528-1532
9. Weinshenker BG, Bass B, Rice GP et al (1989) The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course. Brain 112:1419-1428
10. Runmarker B, Anderson O (1993) Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 116:117-134
11. Bergamaschi R, Berzuini C, Romani A, Cosi V (2001) Predicting secondary progression in relapsing-remitting multiple sclerosis: A Bayesian analysis. J Neurol Sci 189:13-21
12. Cifelli A, Mattews PM (2002) Cerebral plasticity in multiple sclerosis: insights from MRI. Mult Scler 8:193-199
13. Filippi M, Rocca MA (2003) Disturbed function and plasticity in multiple sclerosis as gleaned from functional magnetic resonance imaging. Curr Opin Neurol 16:275-282
14. Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
15. Kurtzke JF, Beeb GW, Nagler B et al (1973) Studies of the natural history of multiple sclerosis. 7. Correlates of clinical change in an early bout. Acta Neurol Scand 49:379-395
16. The IFNB MS Study Group (1993) Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
17. Rio J, Nos C, Tintorè M et al (2002) Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials. Ann Neurol 52:400-406
18. Miller DH (1996) Guidelines for MRI monitoring of the treatment of multiple sclerosis: Recommendations of the US Multiple Sclerosis Society's task force. Mult Scler 1:335-338
19. Filippi M, Horsfield MA, Morrissey SP et al (1994) Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 44:635-641
20. Weiner J, Guttmann CR, Khoury SJ et al (2000) Serial magnetic resonance imaging in multiple sclerosis: Correlation with attacks, disability and disease stage. J Neuroimmunol 104:164-173
21. Truyen L, van Waesberghe JH, van Walderveen MA et al (1996) Accumulation of hypointense lesions ('black holes') on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 47:1469-1476
22. Bakshi R, Benedict RH, Bermel RA, Jacobs L (2001) Regional brain atrophy is associated with physical disability in multiple sclerosis: semiquantitative magnetic resonance imaging and relationship to clinical findings. J Neuroimaging 11:129-136
23. Koudriavtseva T, Thompson AJ, Fiorelli M et al (1997) Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 62:285-287
24. Sriram S, Barcellos LF, Villoslada P et al (2003) Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immun 4:147-152
25. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon β-1b: Experience during the first three years. Neurology 47:889
26. Salama HH, Hong J, Zang YC et al (2003) Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis. Brain 126:2638-2647
27. Giovannoni G, Goodman A (2005) Neutralizing anti-IFN-β antibodies: How much more evidence do we need to use them in practice? Neurology 65:6-8
28. van Boxel-Dezaire AH, van Trigt-Hoff SC, Killestein J et al (2000) Contrasting responses to interferon β-1b treatment in relapsing-remitting multiple sclerosis: Does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment? Ann Neurol 48:313-322
29. Petereit HF, Nolden S, Schoppe S et al (2002) Low interferon-gamma production are better treatment responders: A two-year follow-up of interferon β-treated multiple sclerosis patients. Mult Scler 8:492-494
30. Wandinger KP, Lunemann JD, Wengert O, Bellmann-Strobl J, Aktas O et al (2003) TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-β treatment in multiple sclerosis. Lancet 361:2036-2043
31. Lucchinetti AC, Bruck W, Parisi J et al (2000) Heterogeneity of multiple sclerosis lesions: Implication for the pathogenesis of demyelination. Ann Neurol 47:707-717
32. Cohen BA, Khan O, Jeffery DR et al (2004) Identifying and treating patients with suboptimal responses. Neurology 63[Suppl 6]:S33-S40
33. Bashir K, Buchwald L, Coyle PK et al (2002) MS Patient Management: optimizing immunomodulatory therapy for MS patients. Int J MS Care [Suppl. 4]:3-7
34. International Working Group for Treatment Optimization in MS (2004) Treatment optimization in multiple sclerosis: Report of an international consensus meeting. Eur J Neurol 11:43-47
35. Freedman MS, Patry DG, Grand'Maison F et al (2004) Treatment optimization in multiple sclerosis. Can J Neurol Sci 31:157-168